Clinical Trials
Search our team at AdventHealth Research Institute
-
NCT06014762
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects with Selected Relapsed/Refractory B cell Malignancies
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to find out if an investigational treatment called, P-CD19CD20-ALLO1, is safe and will help treat people with one of the following B cell malignancies: diffuse large B...
-
NCT06619561
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, PK, and Efficacy of Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: Orlando -
NCT06578247
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD Negative Acute Myeloid Leukemia (QuANTUM-Wild)
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to learn more about an investigational drug called QUIZARTINIB. An investigational drug is a drug that is being studied to see if is safe, and to see if your disease or...
-
NCT0645646
A Phase II multicenter open-label trial of tagraxofusp (Tag) in combination with venetoclax and azacitidine (Ven/Aza) in adults with previously untreated CD123+ acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy.
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoOverall, the goal of this research study is to determine if tagraxofusp (Tag) in combination with venetoclax (Ven) and azacitidine (Aza) can safely treat cancer in patients who have not received...
-
NCT06479165
KRT-232-115: A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to determine if navtemadlin in combination with ruxolitinib is a well-tolerated and effective treatment for MF.
-
NCT06624085
A PHASE Ib STUDY EVALUATING THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN IN PATIENTS FROM RACIAL/ETHNIC MINORITIES WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to test glofitamab in Black and Hispanic/Latino participants to find out if it is safe, how well it works, and to understand the way your body processes the drug.
-
NCT05442216
TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoWe are doing this study because we want to find out if this approach will provide a longer period of disease response and is safe. The researchers conducting this study plan to publish the...
-
NCT06226571
A Phase 1, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin 1 (NPM1), and Nucleoporin 98 (NUP98) Genes
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to find the best dose of revumenib taken with other cancer drugs, known as chemotherapy, and to find out what side effects happen after you take this study drug. It will...
-
NCT06384261
A multicenter, open label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy.
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe purpose of this study is to see if the investigational study drug, called cusatuzumab, is safe and effective when given together with other standard of care drugs used to treat Acute Myeloid...
-
NCT06500273
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease after Response to First Line Therapy for Large B-Cell Lymphoma (ALPHA3)
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe study is being conducted in patients diagnosed with large B-cell lymphoma who have completed initial therapy. The study aims to see if CAR T cells made from healthy donors are an effective...
-
NCT06191744
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoThe primary objective of the study is to demonstrate that epcoritamab
with R2 (ER2) will improve CR30 rates compared to chemoimmunotherapy
(CIT) in subjects with previously untreated FL. The primary... -
NCT05332054
Long-Term Follow-up Study (LTFS): An Observational Long-term Follow-up Study of Patients Who Received Prior Caribou Cell Therapy
This study is currently enrolling.Associated Conditions: BMT / HematologyResearch Area: Clinical Cancer ResearchResearch Location: OrlandoCaribou's CAR-T cell product is a genetically modified cell therapy, meaning it is designed to change the expression of a gene or alter natural properties of living cells. Healthy donor T cells have...